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Development of next-generation sequencing and metage-
nomics has revolutionized detection of novel viruses. Among 
these viruses are 3 human protoparvoviruses: bufavirus, 
tusavirus, and cutavirus. These viruses have been detected 
in feces of children with diarrhea. In addition, cutavirus has 
been detected in skin biopsy specimens of cutaneous T-cell 
lymphoma patients in France and in 1 melanoma patient 
in Denmark. We studied seroprevalences of IgG against 
bufavirus, tusavirus, and cutavirus in various populations 
(n = 840), and found a striking geographic difference in 
prevalence of bufavirus IgG. Although prevalence was low 
in adult populations in Finland (1.9%) and the United States 
(3.6%), bufavirus IgG was highly prevalent in populations in 
Iraq (84.8%), Iran (56.1%), and Kenya (72.3%). Conversely, 
cutavirus IgG showed evenly low prevalences (0%–5.6%) 
in all cohorts, and tusavirus IgG was not detected. These 
results provide new insights on the global distribution and 
endemic areas of protoparvoviruses.
Parvoviruses are small, nonenveloped, single-stranded DNA viruses that infect a wide variety of animals 
ranging from insects and shrimp to birds and mammals. 
Human parvoviruses belong to 4 genera: Erythroparvovi-
rus, Bocaparvovirus, Tetraparvovirus, and Dependopar-
vovirus (1). The recently described bufavirus, tusavirus, 
and cutavirus are the first members of the genus Protopar-
vovirus found in humans. All 3 viruses were identified 
by next-generation sequencing and metagenomics in fe-
ces of children with diarrhea: bufavirus from Burkina 
Faso in 2012, tusavirus from Tunisia in 2014, and cutavi-
rus from Brazil and Botswana in 2016 (2–4). In addition, 
cutavirus was detected by in silico analysis of existing 
next-generation sequencing libraries and by PCR of ma-
lignant skin tissues of patients in France with cutaneous 
T-cell lymphoma (4).
To date, 3 genotypes of bufavirus have been detect-
ed, and bufavirus DNA has been detected in 1 nasal swab 
specimen of a child in Finland and in <4% of fecal samples 
from patients with diarrhea in Africa, Europe, and Asia 
(2,5–13). Recently, a bufavirus 3 sequence was reported 
in a fecal sample in Peru, which expanded the geographic 
locations where bufavirus has been detected (14). All of 
these studies have reported DNA sequences of either bu-
favirus 1 or 3; bufavirus 2 DNA has been detected only in 
1 child in Burkina Faso. Humans have been shown to have 
IgG against all 3 bufavirus genotypes, which also seem to 
represent distinct serotypes (12).
Although the seroprevalence of bufavirus in Finland 
was found to be low (3.1% in children and in adults born 
in Finland), the presence of bufavirus IgG in 5/12 adults 
originating from Asia suggested that the bufavirus preva-
lence might be higher in other continents. Furthermore, the 
strong IgG responses indicate that these 3 viruses might 
cause systemic infections similar to other known human 
parvoviruses, such as human parvovirus B19, human bo-
caviruses, and human parvovirus 4 (15). In addition to bu-
favirus in humans, several animal species, including non-
human primates, shrews, bats, rats, swine, and fur seals, 
have been shown to be infected with specific bufavirus-like 
viruses (16–23).
Conversely, tusavirus DNA has been detected only in 
feces of 1 child in Tunisia (3). In addition, 1 of 228 children 
in Finland showed a low-level IgG response (12). How-
ever, these findings are scarce, and more studies are needed 
to determine whether tusavirus is truly a human virus.
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Global Distribution of Human Protoparvoviruses
Cutavirus is the newest member of the human par-
voviruses. This virus was originally detected in feces of 
children with diarrhea in 2016; cutavirus DNA was also 
detected in cancerous tissues of 4/17 patients in France 
with cutaneous T-cell lymphoma (4). Although test re-
sults for other skin cancer types and healthy skin exam-
ined in this study were negative for cutavirus, 1 mela-
noma patient in Denmark was shown to have cutavirus 
DNA in malignant skin (24).
The etiologic roles of bufavirus, tusavirus, and cuta-
virus in human disease remain uncertain and more studies 
are needed. In this study, we developed a new cutavirus 
IgG enzyme immunoassay (EIA) and combined it with 
our existing IgG EIA panel of bufavirus genotypes 1–3 
and tusavirus. We then analyzed 6 human populations on 
4 continents for IgG against these 3 protoparvoviruses. We 
included veterinarians from Finland (n = 324) to assess 
the possible contribution of human–animal contact; adults 
from the United States (n = 84), Iraq (n = 99), and Iran (n 
= 107); and adults (n = 119) and children (n = 107) from 
Kenya to identify age-related and geographic distributions 
of these emerging viruses in humans.
Materials and Methods
Study Cohorts
The cohorts included in the study were from 5 countries on 
4 continents. The study and all sampling were conducted in 
accordance with relevant guidelines and regulations.
For the veterinary cohort from Finland, we obtained 
serum samples from 324 healthy adult volunteers (Table 
1). Samples were collected from participants at the national 
Annual Veterinary Congress in 2009 in Helsinki, Finland 
(25). Most (82%) of the volunteers were veterinarians, 
veterinary students, or veterinary nurses, and 92% 
completed an electronic questionnaire to obtain back-
ground information. Written informed consent was ob-
tained from all study participants, and the study was ap-
proved by the Ethics Committee of Helsinki University 
Central Hospital.
For the cohort from the United States, we obtained se-
rum samples from 84 healthy blood donors at Blood Sys-
tems Research Institute (San Francisco, CA, USA) (Table 
1). The samples were collected during April 2009 in 2 lo-
cations (Arizona [n = 40] and Mississippi [n = 44]). Un-
der US human and health service regulations, the study of 
preexisting, deidentified samples is not classified as human 
subject research.
For the cohort from Iraq, we obtained serum samples 
from 99 healthy adults (Table 1) to assess exposure of the 
population to various virus infections in Nasiriyah, Dhi 
Qar, in southern Iraq (26). Written informed consent was 
obtained from all study participants, and the study was ap-
proved by the Ethics Committees of Medical Sciences at 
Basrah University and the Al-Hussein Teaching Hospital.
For the cohort from Iran, we obtained serum samples 
from 107 healthy adults (Table 1) at the Hamadan Blood 
Transfusion Organization (Hamadan, Iran). Informed con-
sent was waived for analysis of these deidentified blood 
donor samples, and the study was approved by the Ethics 
Committee of Hamadan University of Medical Sciences.
For the cohort from Kenya, we obtained serum 
samples from 107 children and 119 adults who had a 
febrile illness of unknown cause and had visited health 
clinics in Mwatate, Voi, or Wundanyi in Taita Taveta 
County in southern Kenya (Table 1). A questionnaire 
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Table 1. Characteristics of cohorts used in study of global distribution of human protoparvoviruses* 
Cohort 
No. 
persons Health status 





Time of sample 
collection Other features 
Finland 324 Constitutionally healthy 40.2 (19–79) 45 (13.9):279 (86.1) 2009 Oct Adults: 
veterinarians 
United States 84 Constitutionally healthy 41.3 (18–72) 64 (76.2):20 (23.8) 2009 Apr Adults: blood 
donors 




Iran 107 Constitutionally healthy 42.2 (18–77) 50 (46.7):57 (53.3) 2015–2016 Adults: blood 
donors 




6.9 (0.5–17.8) 59 (55.1):43 (40.2); 
5 (4.7)† 
2016 Apr–Aug Children: includes 
9 HIV+ (8 
receiving HAART) 




43.3 (18.2–88.3) 42 (35.3):76 (63.9); 
1 (0.8)† 
2016 Apr–Nov Adults: includes 
38 HIV+ (35 
receiving HAART) 
*HAART, highly active antiretroviral therapy; +, positive. 
†Sex was not specified in the questionnaire. 
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to obtain background information and symptoms was 
completed by all patients, and written informed consent 
was obtained from all study participants or guardians 
of children. The study was approved by the Kenyatta 
National Hospital–University of Nairobi Ethics and Re-
search Committee.
Serologic Analysis
Cutavirus Capsid Protein 2 Virus-Like Particles
To analyze serum samples for IgG against all human 
protoparvoviruses, we included cutavirus in an in-house 
EIA panel for bufavirus genotypes 1–3 and tusavirus 
(12). The virus capsid protein 2 (VP2) gene for cuta-
virus was cloned from the original DNA extract from 
feces of the cutavirus DNA–positive child from Brazil 
(Br337) (4) by using primers VP2 fwd Br337 BamHI 
(5′-TAggatccATGTCAGAACCAGCTAATGATAC-3′) 
and VP2 rev Br337 SalI (5′-CTCgtcgacTTACAATGT-
GTAGTTTGGTAGACA-3′) (restriction sites are indi-
cated by lowercase letters).
The obtained VP2 (GenBank accession no. 
MH127919) was used to create a recombinant baculo-
virus with the Bac-to-Bac system (Invitrogen, Carlsbad, 
CA, USA), according to the manufacturer’s instructions, 
and cutavirus VP2 virus-like particles (VLPs) were ex-
pressed and purified as described for bufavirus VP2 VLPs 
and tusavirus VP2 VLPs (12).
Combined Bufavirus 1–3/Tusavirus–Cutavirus IgG EIA
We analyzed all serum samples by using the combined bufavi-
rus 1–3/tusavirus–cutavirus IgG EIAs, with insect cell lysate 
as a control antigen, as described, but included cutavirus VLP 
antigen in separate wells (12). In brief, we applied biotinyl-
ated antigens (VP2 VLPs, 80 ng/well) or cell lysate control to 
streptavidin-coated plates. After incubation and postcoating, 
we applied serum diluted 1:200 to each well. To detect bound 
IgG, we used horseradish peroxidase–conjugated antihuman 
IgG as the secondary antibody and 3,3′,5,5′-tetramethylben-
zidine (Dako, Santa Clara, CA, USA) as the substrate.
We measured optical densities (ODs) at 450 nm (Multi-
skan EX; Thermo Fischer Scientific, Pittsburgh, PA, USA) 
and subtracted blank ODs from test ODs to get the final 
OD. We confirmed all samples with an OD >0.1 by using a 
competition assay, as described (12,27). In the competition 
assay, serum antibodies were blocked separately with 3 un-
biotinylated antigens in solution: the same (homologous) 
antigen as in the EIA, the heterologous antigen of the phy-
logenetically closest protoparvovirus, and the heterologous 
antigen of a more distant protoparvovirus, before repeat-
ing the EIAs. A sample was considered IgG positive when 
full homologous blocking but no (or partial) heterologous 
blocking occurred, as described (12).
Statistical Analysis
We performed statistical analysis by using 2 × 2 tables 
and test statistics (mid p-exact value) in OpenEpi software 
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Figure 1. Identification of 
cutavirus from human serum 
samples. A) Sodium dodecyl 
sulfate–polyacrylamide gel 
electrophoresis of virus capsid 
protein 2. Lane M, protein size 
marker; lane C, cutavirus. B) 
Electron micrograph of cutavirus 
virus-like particles. Scale bar 
indicates 100 nm.
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(https://www.OpenEpi.com). A 2-tailed p value <0.05 was 
considered statistically significant.
Results
Cutavirus IgG EIA and Cross-Reactivity of IgG
Sodium dodecyl sulfate–polyacrylamide gel electropho-
resis identified cutavirus VP2s of expected size (≈64 kDa) 
(Figure 1, panel A). Electron microscopy identified par-
vovirus-like VLPs with a diameter of ≈25 nm (Figure 1, 
panel B).
In the cutavirus IgG EIA, it was evident that bufavi-
rus 2 and cutavirus cross-react: in all samples with an OD 
>0.5 for bufavirus 2 or cutavirus, a reaction was always ob-
served with the other antigen. In samples showing weak re-
activity (OD 0.1–0.5) in cutavirus or bufavirus 2 IgG EIAs, 
both cross-reactivities and single-specific reactivities were 
observed. In the competition assay, the specific reactivity 
of bufavirus or cutavirus was blocked completely only by 
homologous antigen, whereas cross-reactive reactions were 
blocked by homologous and heterologous antigens. In sev-
eral instances, heterologous antigen slightly reduced the 
specific EIA reactivity; however, this reduction was much 
less than that caused by homologous antigen.
In cohorts from the Middle East and Africa that 
showed high prevalences of bufavirus IgG, some cross-
reactivity was also observed among the 3 bufavirus geno-
types, mostly for samples with higher ODs. However, the 
competition assay used for all positive samples could dis-
tinguish genotype-specific reactivity for correct interpreta-
tion. Tusavirus IgG did not cross-react with bufavirus IgGs 
or cutavirus IgG.
Bufavirus IgG in Adults
Bufavirus IgG was rare among veterinarians from Finland 
and blood donors from the United States: only 1.9% of 
the veterinarians and 3.6% of the blood donors had bu-
favirus IgG (Table 2). In these cohorts, each bufavirus 
IgG–positive person had antibodies against only 1 bufa-
virus genotype. No indications of specific animal contact 
being associated with bufavirus seropositivity were found 
when we compared background information for bufavirus 
IgG–positive and bufavirus IgG–negative veterinarians. 
For blood donors from the United States, all 3 bufavirus 
IgG–positive samples were from Mississippi. However, 
all samples from Arizona were negative for bufavirus 
IgG. The most commonly detected genotype was bufa-
virus 1 in Finland and bufavirus 3 in the United States 
(Table 2).
In striking contrast to adults from the United States 
and Finland, including our previous results for students 
and staff members from Finland (12), bufavirus IgG was 
common in Iraq, Iran, and Kenya, for which 84.8%, 56.1%, 
and 72.3%, respectively, of adult populations had IgG 
against >1 bufavirus genotypes (Table 2). In the Middle 
East, bufavirus 1 was the most common type, whereas in 
Kenya, bufavirus 3 was the predominant genotype (Table 
2). Bufavirus 2 was the second most prevalent bufavirus 
in all 3 high-prevalence countries. In Iraq, we found that 
30 (30.3%) of 99 persons had antibodies against 2 bu-
favirus genotypes, and 7 (7.0%) of 99 persons had anti-
bodies against all 3 bufavirus genotypes. In adults from 
Kenya, we found similar prevalences: 30 (25.2%) of 119 
persons had antibodies against 2 bufavirus genotypes, and 
6 (5.0%) of 119 persons had antibodies against all 3 bufa-
virus genotypes. However, in Iran, we found that double 
or triple prevalences were lower: 14 (13.1%) of 107 per-
sons had antibodies against 2 bufavirus genotypes, and 2 
(1.9%) of 107 persons had antibodies against all 3 bufavi-
rus genotypes.
In Kenya, HIV-positive patients had a similar bufavi-
rus IgG prevalence as the rest of the cohort: 78.9% (30/38) 
in HIV-positive adults (mean age 46.3 years, range 27–85 
years) vs. 69.1% (56/81) in HIV-negative adults (mean 
age 41.9 years, range 18–88 years) (p = 0.275). When we 
compared only the 38 HIV-positive persons and 60 HIV-
negative persons within the same age range (27–85 years), 
bufavirus seroprevalences were even more similar: 79% for 
HIV-positive persons and 75% for HIV-negative persons 
(p = 0.669). However, possible undiagnosed cases of infec-
tion with HIV and unequal numbers could affect the accu-
racy of this comparison.
When the adult cohorts were analyzed more closely 
and persons were divided by age into equal-sized groups 
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IgG against bufavirus genotypes Tusavirus 
IgG 
Cutavirus 
IgG‡ 1 2‡ 3 
Finland, healthy adults (veterinarians) 324 6 (1.9) 4 (1.2) 1 (0.3)§ 1 (0.3) 0 16 (4.9)§ 
United States, healthy adults 84 3 (3.6) 0 0 3 (3.6) 0 0 
Iraq, healthy adults 99 84 (84.8) 80 (80.8) 33 (33.3)¶ 15 (15.2) 0 1 (1.0)¶ 
Iran, healthy adults 107 60 (56.1) 55 (51.4) 17 (17.9) 6 (5.6) 0 6 (5.6) 
Kenya, febrile children <18 y of age 107 22 (20.6) 3 (2.8) 4 (3.7) 20 (18.7) 0 2 (1.9) 
Kenya, febrile adults 119 86 (72.3) 31 (26.1) 43 (36.1)# 56 (47.1) 0 5 (4.2)# 
*Values are no. (%) unless otherwise noted.. 
†Includes persons that were IgG+ against >1 bufavirus genotypes. 
‡Unclear bufavirus 2 and cutavirus blocking results were observed for 1§ (0.3%), 2¶ (2.0%), and 3# (2.5%) persons. These values are not included in 
overall seroprevalence calculations. 
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of <40 years of age and >40 years of age, we found that 
for younger adults in Iran, bufavirus seroprevalence was 
lower than that for older adults (21/54 [38.9%] vs. 39/53 
[73.6%]; p = 0.0003). However, a similar distinction was 
not observed for adults from Iraq or Kenya (Table 3). For 
veterinarians from Finland and adults from the United 
States, we found that younger adults also had a lower bu-
favirus seroprevalence, albeit without statistical power, 
because of the low overall prevalence of bufavirus IgG in 
these countries. When we divided the cohorts into persons 
<30 years of age and >30 years of age, a similar trend 
was also observed for adults in Kenya (14/35 [56.0%] vs. 
70/92 [76.1%]; p = 0.0595). This trend was not observed 
for persons in Iraq.
Bufavirus IgG in Children in Kenya
In Kenya, the bufavirus IgG prevalence in children was 
significantly lower than that in adults (20.6% in children 
<18 years of age vs. 72.3% in adults; p<0.0001), but we 
observed similar proportions of bufavirus and a predomi-
nance of bufavirus 3 in both adults and children. (Table 
2). When we divided the cohort of children into those <5 
years of age and those 5–17 years of age, the prevalence 
of bufavirus IgG by age increased from 12% to 28.1% 
(Figure 2).
Cutavirus and Tusavirus IgG in Adults and Children
The prevalence of cutavirus IgG was generally low for all 
groups, ranging from 1.0% in Iraq to 5.6% in Iran, and cuta-
virus IgG was not detected in adults in the United States 
(Table 2). In veterinarians in Finland, cutavirus IgG (4.9%) 
was more common than bufavirus IgG (1.9%) (p = 0.032). 
Two adults from Kenya and 1 veterinarian from Finland 
had both cutavirus IgG and bufavirus 2 IgG in their sam-
ples, which showed that these 2 antigenically similar vi-
ruses can infect the same person and elicit specific immune 
responses against each virus. However, for 6 patients (1 in 
Finland, 2 in Iraq, and 3 in Kenya), we could not determine 
whether the reactivity detected was specific for bufavirus 
2, cutavirus, or both. These results were not included in the 
final prevalence calculations (Table 2). Tusavirus IgG was 
not detected in any cohort (Table 2).
Discussion
During the current decade, several new parvoviruses 
have been detected, mostly because of the development 
of NGS methods. Bufavirus, tusavirus, and cutavirus are 
the newest of these viruses detected in human samples 
(2–4). Bufavirus has been associated with gastroenteritis, 
and cutavirus is being studied for its relationship to skin 
cancers (4,8–10,12,24). However, studies that attempted 
to detect Bufavirus, tusavirus, and cutavirus DNA in any 
sample type or virus antibodies in serum samples have 
been infrequent (13).
We found high (50%–85%) seroprevalences of bufavi-
rus IgG in cohorts from the Middle East and Africa, which 
indicated that bufavirus infections are endemic to these ar-
eas. The observed low (1.9%) seroprevalence in veterinar-
ians in Finland is consistent with our previous results for 
staff members and medical students born in Finland (3.1%) 
(12). The seroprevalence of bufavirus in the United States 
was similar to that in Finland, although the major genotype 
was different. In contrast to the diverse epidemiology of 
antibodies against bufavirus, antibodies against cutavirus 
appeared globally and were much more evenly distributed 
and showed a low prevalence. These results provide new 
insights on the global distribution and identify areas to 
which protoparvoviruses are endemic.
Because the difference in seroprevalence between 
persons born in Finland and staff born in Asia in our pre-
vious study could also be caused by more frequent animal 
contacts for 5 persons from Asia (12), we included veteri-
narians in this current study. However, no specific animal 
contacts for veterinarians from Finland were associated 
with bufavirus IgG or cutavirus IgG seropositivity. Al-
though species jumps have occurred within protoparvo-
viruses (28), this result is consistent with the general rule 
of host-order specificity of parvoviruses (1). No animal 
contact information was available for persons from the 
Middle East, Kenya, or the United States.
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Table 3. Seroprevalence of bufavirus IgG in adult cohorts, by age, in study of global distribution of human protoparvoviruses* 
Cohort Age group, y No. persons No. (%) bufavirus IgG+ (95% CI) p value Mean age, y (range) 
Finland <40 165 1 (0.6) (0.0–3.7) 0.096 31.6 (19–39) 
>40 149 5 (3.4) (1.2–7.8) 49.7 (40–79) 
United States <40 38 1 (2.6) (0.0–14.7) 0.731 26.4 (18–39) 
>40 46 2 (4.3) (0.4–15.3) 53.5 (40–72) 
Iraq <40 45 40 (88.9) (76.1–95.6) 0.325 30.8 (18–39) 
>40 54 44 (81.5) (69.0–89.8) 47.2 (40–60) 
Iran <40 54 21 (38.9) (27.0–52.2) 0.0003 30.1 (18–39) 
>40 53 39 (73.6) (60.3–83.7) 55.0 (40–77) 
Kenya <40 52 37 (71.2) (57.7–81.8) 0.890 29.5 (18–39) 
>40 65 47 (72.3) (60.4–81.8) 54.3 (40–88) 
*The exact age of 2 adults from Kenya and 10 veterinarians from Finland were not known and they were excluded from the analysis. However, the 2 
Kenyans were defined as adults in the overall prevalence calculations on the basis of education and marital status in the questionnaire. All veterinarians 
were defined as adults on the basis of work-related sample collection site. +, positive. 
 
Global Distribution of Human Protoparvoviruses
The age group results from Kenya, which showed con-
tinuously increasing seroprevalences of all 3 bufavirus gen-
otypes, also showed that bufaviruses infect persons of all 
ages. The lower seroprevalence in children <5 years of age 
than in older children and adults indicates that the age of 
acquisition of bufavirus greatly differs from that of human 
bocavirus 1 (27) but resembles that for human parvovirus 
B19. Also for persons 5–17 years of age, an age-dependent 
increase was evident, but statistical power was insufficient 
to further divide these children into narrower age groups. In 
adults, the age-dependent increase in seroprevalence was 
detectable in Iran, but not in Kenya or Iraq. This difference 
could be caused by decreased bufavirus circulation in Iran 
during the past 30–40 years or to socioeconomic or cultural 
changes over time. In Finland and the United States, age 
group prevalences were similar, albeit at low levels.
HIV-positive adults in Kenya did not have a high-
er seroprevalence of bufavirus IgG than HIV-negative 
adults. Bufavirus infection route(s) could therefore be hy-
pothesized to differ from those for HIV infection.
The predominant bufavirus genotype (1 or 3) varied 
between countries studied. Bufavirus 2 was the second 
most common genotype in the 3 high-prevalence coun-
tries (Iraq, Iran, and Kenya). In sharp contrast, bufavirus 
2 DNA has hitherto been found in the fecal sample of 
only 1 child in Burkina Faso, whereas all other bufavirus 
DNA–positive samples had genotypes 1 or 3 (2,5,6,8–
11,14). Our serologic data indicate that bufavirus 2 in-
fections exist and are common in certain areas. Further 
studies of patients with primary infection should eluci-
date whether sample type(s) most suitable for detection 
of bufavirus 2, and also for genotypes 1 and 3, is stool or 
another type of sample.
In humans, IgG is induced against all 3 bufavirus 
genotypes and cutavirus, and immune reactions appear to 
be strong. In our previous report on bufavirus IgG, the 3 
bufavirus genotypes were shown to have no mutual cross-
reactivity (12). In this study, some cross-reactivity was 
observed between the 3 bufavirus genotypes, particularly 
among high OD samples in high-seroprevalence cohorts. 
In addition, cutavirus and bufavirus 2 cross-reactivity was 
common, which is consistent with the fact that amino acid 
identities are high within the VP2 gene (82% identity for 
the amino acid sequence). However, both genotype and 
species cross-reactivities could be distinguished from spe-
cific reactivity in the competition assay, similarly to what is 
shown for the 4 human bocaviruses (28).
Despite some VLP cross-reactivity in the EIA, the 
3 bufavirus genotypes do not appear to be cross-protec-
tive. Several persons had antibodies against 2 or even 3 
protoparvoviruses. Whether the previously formed an-
tibodies against the first virus protects the human host 
against possible symptoms of the second related virus 
infection, or worsen the symptoms through antibody-
dependent enhancement, is not known. However, it ap-
pears that immunity toward different protoparvoviruses 
does not hamper a sequential infection by heterologous 
virus (bufavirus genotype or cutavirus) or formation of 
specific antibodies toward this virus, which is in contrast 
to the phenomenon of original antigenic sin seen among 
human bocaviruses (27,29). Longitudinal studies are 
needed to assess antibody and protection patterns, both 
during acute primary infections and during subsequent 
infections by the other human protoparvoviruses. It will 
be useful to determine the clinical pictures in these con-
texts, whether these viruses cause similar primary symp-
toms and illnesses, and whether they have the same or 
different tissue tropisms.
We did not detect tusavirus IgG in any cohort. This 
finding is consistent with results of 2 previous human stud-
ies, which reported no or infrequent evidence of tusavirus 
(3,12). In addition, a study has reported sequences with 
some resemblance to tusavirus: a metagenomic analy-
sis of fur seals in Brazil described partial sequences with 
39%–82% amino acid similarity to tusavirus (23). Further 
studies on tusavirus DNA or antibodies are needed to de-
termine whether tusavirus is a human or an animal parvo-
virus whose original detection in human feces was caused 
by consumption of meat or other products of a tusavirus-
infected animal.
In conclusion, we observed major differences in serop-
revalence of bufavirus when we compared Finland and the 
United States with the Middle East and Kenya. The high 
seroprevalence of bufavirus in the Middle East and Africa 
provides new opportunities for detecting bufavirus primary 
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Figure 2. Seroprevalence of bufavirus in Kenya, by age. Several 
persons (mostly adults) had IgG against >1 bufavirus genotypes; 
such persons are counted as 1 person in the bufavirus column. 
Differences in overall bufavirus seroprevalences were statistically 
significant between younger children vs. older children (p = 
0.04345), younger children vs. adults (p<0.000001), and older 
children vs. adults (p<0.000001).
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infections because these infections seem to be endemic to 
these regions. The predominant bufavirus genotype varied: 
bufavirus 1 was the most prevalent type in Finland and 
in the Middle East, and bufavirus 3 was the most preva-
lent type in the United States and in Kenya. Although IgG 
cross-reactivity was commonly observed, virus-specific 
antibodies could be distinguished from cross-reactivity by 
the competition assay. In contrast to bufavirus infections, 
cutavirus infections were distributed evenly and at found at 
low prevalences in all countries studied; for blood donors 
in the United States no virus IgG was detected. Tusavirus 
IgG was not detected in any cohorts studied.
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Viruses of the family Parvoviridae (Latin parvum [meaning small or tiny]) are among the smallest viruses described, 18–28 nm in 
diameter. There are 2 subfamilies of the family Parvoviridae: Parvo-
virinae and Densovirinae (Latin denso [thick or compact]). Parvo-
virinae may infect humans, but Densovirinae infect only arthropods. 
Structurally, these viruses are nonenveloped, icosahedral viruses that 
contain a single-stranded linear DNA genome.
The small size of these viruses might account for their late 
discovery. In 1974, the first pathogenic human parvovirus was 
discovered and named B19 from the coding of a serum sample, 
number 19 in panel B, that gave anomalous results during testing 
for hepatitis B. Although human B19 infections are more often as-
ymptomatic or lead to mild rash illnesses and arthralgias, they can 
also cause severe anemia in fetuses and in persons with underlying 
hemoglobinopathies.
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